Search
Regenxbio Inc
RGNXAdd to Watchlist
5.650USD
-0.070-1.22%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
291.64MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.22%
5 Days
-43.95%
1 Month
-40.46%
6 Months
-49.78%
Year to Date
-60.76%
1 Year
-36.45%
TradingKey Stock Score of Regenxbio Inc
Currency: USD Updated: 2026-05-15Key Insights
Regenxbio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 94 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.27.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regenxbio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Regenxbio Inc Highlights
StrengthsRisks
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 88.87% year-on-year.
Overvalued
The company’s latest PE is -1.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.28M shares, decreasing 7.13% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.02K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.49.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
26.083
Target Price
+356.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Regenxbio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regenxbio Inc Info
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Ticker SymbolRGNX
CompanyRegenxbio Inc
CEOSimpson (Curran M)
Websitehttps://regenxbio.com/
Related Instruments
-1.67%
+1.29%
+0.97%
-0.47%
+0.72%
+1.06%
-0.59%
+0.07%
-1.03%
0.00%
+0.54%
-0.08%
+1.99%
+1.19%
+2.02%
0.00%
-9.82%
-0.24%
-2.88%
+2.34%Popular Instruments
102.263
-0.193 (-0.19%)
297.840
-2.390 (-0.80%)
222.320
-3.000 (-1.33%)
4571.070
+4.950 (+0.11%)
458.680
-23.340 (-4.84%)
1333.010
-74.600 (-5.30%)
681.540
-43.120 (-5.95%)
396.940
+0.160 (+0.04%)
76849.660
-30.260 (-0.04%)
409.990
-12.250 (-2.90%)
